CA2967170C - Calcifediol soft capsules - Google Patents

Calcifediol soft capsules Download PDF

Info

Publication number
CA2967170C
CA2967170C CA2967170A CA2967170A CA2967170C CA 2967170 C CA2967170 C CA 2967170C CA 2967170 A CA2967170 A CA 2967170A CA 2967170 A CA2967170 A CA 2967170A CA 2967170 C CA2967170 C CA 2967170C
Authority
CA
Canada
Prior art keywords
soft capsule
pharmaceutically acceptable
calcifediol
group
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2967170A
Other languages
English (en)
French (fr)
Other versions
CA2967170A1 (en
Inventor
Josep Maria Sune Negre
Ignacio Ortega Azpitarte
Pepa Del Arenal Barrios
Gonzalo Hernandez Herrero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Faes Farma SA
Original Assignee
Faes Farma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52462260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2967170(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Faes Farma SA filed Critical Faes Farma SA
Publication of CA2967170A1 publication Critical patent/CA2967170A1/en
Application granted granted Critical
Publication of CA2967170C publication Critical patent/CA2967170C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Paints Or Removers (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Lubricants (AREA)
CA2967170A 2015-02-06 2016-02-05 Calcifediol soft capsules Active CA2967170C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382042.8 2015-02-06
EP15382042.8A EP3053598A1 (en) 2015-02-06 2015-02-06 Calcifediol soft capsules
PCT/EP2016/052458 WO2016124724A1 (en) 2015-02-06 2016-02-05 Calcifediol soft capsules

Publications (2)

Publication Number Publication Date
CA2967170A1 CA2967170A1 (en) 2016-08-11
CA2967170C true CA2967170C (en) 2018-06-05

Family

ID=52462260

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2967170A Active CA2967170C (en) 2015-02-06 2016-02-05 Calcifediol soft capsules

Country Status (32)

Country Link
US (1) US10525018B2 (enExample)
EP (3) EP3053598A1 (enExample)
JP (2) JP6427270B2 (enExample)
KR (1) KR101971384B1 (enExample)
CN (2) CN112843014A (enExample)
AU (1) AU2016214336B2 (enExample)
BR (1) BR112017010657B1 (enExample)
CA (1) CA2967170C (enExample)
CL (1) CL2017001335A1 (enExample)
CO (1) CO2017004545A2 (enExample)
CY (1) CY1122976T1 (enExample)
DK (2) DK3204047T3 (enExample)
EA (1) EA034821B1 (enExample)
ES (2) ES2738642T3 (enExample)
FI (1) FI3204047T4 (enExample)
HR (1) HRP20200859T4 (enExample)
HU (1) HUE050133T2 (enExample)
LT (1) LT3204047T (enExample)
MA (2) MA41058B1 (enExample)
MD (1) MD3204047T2 (enExample)
ME (1) ME03739B (enExample)
MX (1) MX367999B (enExample)
MY (2) MY199862A (enExample)
PE (1) PE20170911A1 (enExample)
PH (1) PH12017501350A1 (enExample)
PL (1) PL3204047T3 (enExample)
PT (1) PT3204047T (enExample)
RS (2) RS64166B1 (enExample)
SI (1) SI3204047T1 (enExample)
SM (1) SMT202000278T1 (enExample)
WO (1) WO2016124724A1 (enExample)
ZA (1) ZA201703444B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3053598A1 (en) 2015-02-06 2016-08-10 Faes Farma, S.A. Calcifediol soft capsules
CN108542908A (zh) * 2018-06-08 2018-09-18 唐飞 25-羟基维生素d3在制备治疗或预防肝性骨病药物中的应用
EP3843706A1 (en) 2018-08-31 2021-07-07 OPKO Ireland Global Holdings, Ltd. Vitamin d pediatric dosage forms, methods of making and using
CN109662953B (zh) * 2019-02-18 2022-05-10 威海金思力生物科技股份有限公司 一种维生素d软胶囊及其制作方法
WO2021011538A1 (en) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Capsule dosage forms, methods of preparation and methods of use thereof
CN114269348A (zh) * 2019-08-22 2022-04-01 工业技术和生物技术公司 用于治疗和预防癌症的激素d(维生素d)及其衍生物
CN113559079B (zh) * 2020-04-28 2023-10-20 江苏恒瑞医药股份有限公司 一种软胶囊及其制备方法和用途
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
LT4243797T (lt) 2020-11-16 2026-06-10 Orcosa Inc. Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui
WO2022224001A1 (en) 2021-04-22 2022-10-27 Faes Farma, S.A. Universal dosage regime of 25-hydroxy vitamin d3
CN114159402A (zh) * 2021-12-21 2022-03-11 湖州展望天明药业有限公司 一种不透明植物胶囊及其制备方法
CN116350598A (zh) * 2021-12-28 2023-06-30 人福普克药业（武汉）有限公司 一种用于维生素d类药物的成膜组合物及其药物制剂和制备方法
CN114712505B (zh) * 2022-03-10 2023-09-05 南方医科大学南方医院 维生素d受体激动剂在制备预防和/或治疗炎症性骨丢失的药物中的应用
AU2023397554B2 (en) 2022-12-14 2026-01-29 R.P. Scherer Technologies, Llc Softgel capsules and a method for preparing the softgel capsules
CN116270520A (zh) * 2023-03-03 2023-06-23 正大制药（青岛）有限公司 一种维生素d胶囊型滴剂及其制备方法
CN121466026B (zh) * 2026-01-12 2026-07-24 厦门紫旭医药科技有限公司 一种双层软胶膜及其制备方法和应用与大装量胶囊

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4532126A (en) 1982-05-07 1985-07-30 R. P. Scherer Corporation Masticatory soft elastic gelatin capsules and method for the manufacture thereof
GB8305693D0 (en) 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
JPS6335411A (ja) 1986-07-29 1988-02-16 Tonen Sekiyukagaku Kk 高純度合成石英の製造方法
US4997824A (en) 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
JPH04288016A (ja) 1991-03-14 1992-10-13 Tokai Capsule Kk 活性型ビタミンｄ３類軟カプセル剤の製造方法
JPH054925A (ja) 1991-06-27 1993-01-14 Teikoku Chem Ind Corp Ltd アルフアカルシドール軟カプセル製剤
JP2684587B2 (ja) 1993-06-21 1997-12-03 呉羽化学工業株式会社 腎性骨異栄養症における骨量減少抑制剤
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
DE60045101D1 (de) * 1999-08-31 2010-11-25 Chugai Pharmaceutical Co Ltd Weichkapseln
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
CN100391464C (zh) 2001-12-03 2008-06-04 诺瓦西股份有限公司 含活性维生素d化合物的药物组合物
US7632518B2 (en) * 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
AU2003230191A1 (en) 2002-02-20 2003-09-09 Strides Arcolab Limited Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
US20030158264A1 (en) * 2002-02-20 2003-08-21 Ramachandran Radhakrishnan Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
WO2003086415A1 (en) 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US7438903B2 (en) 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US7332482B2 (en) 2003-09-24 2008-02-19 Bioxell S.P.A. Method for treating benign prostatic hyperplasia
US20050142185A1 (en) 2003-12-29 2005-06-30 Beleno Alfredo B. Softgel formulations of bisphosphonates bone resorption inhibitors
US20050152969A1 (en) 2004-01-08 2005-07-14 Chiprich Timothy B. Colored liquid-filled soft capsules and method of manufacture thereof
US20050175686A1 (en) 2004-02-11 2005-08-11 Ramachandran Radhakrishnan Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule
US20060009425A1 (en) 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
MXPA06014185A (es) 2004-06-07 2007-04-16 Strides Arcolab Ltd Composicion farmaceutica que contiene una solucion estable y clara de medicamento anti-inflmatorio en capsulas de gelatina blanda, y proceso para producirlo.
AU2006294819A1 (en) 2005-09-26 2007-04-05 Novacea, Inc. Prevention and treatment of gastrointestinal and bladder disorders using active vitamin D compounds
US20070098819A1 (en) * 2005-11-02 2007-05-03 Susan Thys-Jacobs Micronutrient supplement with calcium, vitamin D or calcium & vitamin D combination for premenstrual syndrome, postpartum depression, depression and panic attacks
PT3095447T (pt) * 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
WO2008097646A1 (en) * 2007-02-09 2008-08-14 Schering Corporation Methods to treat and/or prevent mucositis
KR101691876B1 (ko) 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
DK2321273T3 (en) 2008-07-24 2015-02-16 Wisconsin Alumni Res Found Once weekly administration of 25-hydroxy vitamin D 3 for maintaining an elevated blood level concentration at steady state pharmaco-kinetics
CN102307576A (zh) 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
US9011908B2 (en) 2009-04-06 2015-04-21 Banner Life Sciences Llc Progesterone solutions for increased bioavailability
WO2012047098A1 (en) 2010-10-04 2012-04-12 Dishman Pharmaceuticals And Chemicals Ltd. Encapsulated fat-soluble vitamin
GB201216385D0 (en) 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
EP3053598A1 (en) 2015-02-06 2016-08-10 Faes Farma, S.A. Calcifediol soft capsules

Also Published As

Publication number Publication date
BR112017010657B1 (pt) 2022-10-11
FI3204047T4 (fi) 2026-07-13
JP6427270B2 (ja) 2018-11-21
BR112017010657A2 (pt) 2018-02-14
MA41058B1 (fr) 2020-05-29
PT3204047T (pt) 2020-06-05
CO2017004545A2 (es) 2017-08-31
EP3689380A1 (en) 2020-08-05
JP2017536358A (ja) 2017-12-07
EP3689380B1 (en) 2023-03-15
DK3689380T3 (da) 2023-05-22
ES2738642T3 (es) 2020-11-06
SMT202000278T1 (it) 2020-07-08
US20170348249A1 (en) 2017-12-07
SI3204047T1 (sl) 2020-07-31
EP3204047B1 (en) 2020-05-27
US10525018B2 (en) 2020-01-07
MX2017006272A (es) 2017-08-14
MX367999B (es) 2019-09-12
RS64166B1 (sr) 2023-05-31
MY189432A (en) 2022-02-11
KR20170093123A (ko) 2017-08-14
CY1122976T1 (el) 2021-10-29
HRP20200859T4 (hr) 2026-07-31
AU2016214336A1 (en) 2017-05-25
PH12017501350A1 (en) 2017-12-18
WO2016124724A1 (en) 2016-08-11
ZA201703444B (en) 2019-09-25
EA034821B1 (ru) 2020-03-25
EA201791097A1 (ru) 2017-08-31
PL3204047T3 (pl) 2020-08-24
MD3204047T2 (ro) 2020-06-30
CN106999441B (zh) 2020-11-24
CL2017001335A1 (es) 2018-01-19
JP6697779B2 (ja) 2020-05-27
HRP20200859T1 (hr) 2020-08-21
EP3053598A1 (en) 2016-08-10
CN112843014A (zh) 2021-05-28
ES2941385T3 (es) 2023-05-22
JP2018184458A (ja) 2018-11-22
HUE050133T2 (hu) 2020-11-30
KR101971384B9 (ko) 2022-07-25
EP3204047A1 (en) 2017-08-16
MA52507A (fr) 2021-03-10
MY199862A (en) 2023-11-25
LT3204047T (lt) 2020-07-10
DK3204047T3 (da) 2020-06-02
RS60467B1 (sr) 2020-07-31
KR101971384B1 (ko) 2019-04-22
AU2016214336B2 (en) 2017-10-19
ME03739B (me) 2021-01-20
CN106999441A (zh) 2017-08-01
ES2738642T1 (es) 2020-01-24
EP3204047B2 (en) 2026-05-06
PE20170911A1 (es) 2017-07-12
CA2967170A1 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
AU2016214336B2 (en) Calcifediol soft capsules
NL2023661B1 (en) Pharmaceutical Eutectic Salt Formulation
US20160367480A1 (en) Vitamin c delivery system and liposomal composition thereof
WO2012013331A2 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases
RS57881B1 (sr) Formulacija solubilizovane kapsule 1,1-dimetiletil [(1s)-1-{[(2s,4r)-4-(7-hloro-4metoksiizohinolin-1-iloksi)-2-({(1r,2s)-1-[(ciklopropilsulfonil)karbamoil]-2-etenilciklopropil}karbamoil)pirolidin-1-il]karbonil}-2,2-dimetilpropil]karbamata
TW201521719A (zh) 含有脂質化合物、三酸甘油酯及界面活性劑之組成物與使用該組成物之方法
CN113164402A (zh) 药物制剂
CN106999502A (zh) 药物组合物和方法
Park et al. In vitro and in vivo comparative study of itraconazole bioavailability when formulated in highly soluble self‐emulsifying system and in solid dispersion
JPH0840936A (ja) 経口投与薬物のための製剤
KR20040101300A (ko) 경질 쉘 캡슐용 이부프로펜 용액
WO2015121378A1 (en) Liquid phospholipid-containing compositions for the preparation of pharmaceuticals
HK40034919B (en) Calcifediol soft capsules
HK40034919A (en) Calcifediol soft capsules
HK1235289A1 (en) Calcifediol soft capsules
HK1235289B (en) Calcifediol soft capsules
HK1157185B (en) Compositions of gnrh related compounds and processes of preparation
HK1157185A1 (en) Compositions of gnrh related compounds and processes of preparation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170510

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250131

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250131